Global Antibody and Recombinant Protein CDMO Market 2023 by Company, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Antibody and Recombinant Protein CDMO market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Antibody and Recombinant Protein CDMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Antibody and Recombinant Protein CDMO market size and forecasts, in consumption value ($ Million), 2018-2029
Global Antibody and Recombinant Protein CDMO market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Antibody and Recombinant Protein CDMO market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Antibody and Recombinant Protein CDMO market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Antibody and Recombinant Protein CDMO
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Antibody and Recombinant Protein CDMO market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Batavia Biosciences, Grifols, Cerbios-Pharma SA, HALIX and Biovian Oy, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Antibody and Recombinant Protein CDMO market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Antibody and Recombinant Protein CDMO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Antibody and Recombinant Protein CDMO, with revenue, gross margin and global market share of Antibody and Recombinant Protein CDMO from 2018 to 2023.
Chapter 3, the Antibody and Recombinant Protein CDMO competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Antibody and Recombinant Protein CDMO market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Antibody and Recombinant Protein CDMO.
Chapter 13, to describe Antibody and Recombinant Protein CDMO research findings and conclusion.
This report is a detailed and comprehensive analysis for global Antibody and Recombinant Protein CDMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Antibody and Recombinant Protein CDMO market size and forecasts, in consumption value ($ Million), 2018-2029
Global Antibody and Recombinant Protein CDMO market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Antibody and Recombinant Protein CDMO market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Antibody and Recombinant Protein CDMO market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Antibody and Recombinant Protein CDMO
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Antibody and Recombinant Protein CDMO market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Batavia Biosciences, Grifols, Cerbios-Pharma SA, HALIX and Biovian Oy, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Antibody and Recombinant Protein CDMO market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Antibody CDMO
- Recombinant Protein CDMO
- Pharmaceutical Company
- Biotechnology Company
- Generic Company
- Batavia Biosciences
- Grifols
- Cerbios-Pharma SA
- HALIX
- Biovian Oy
- Catalent
- Goodwin Biotechnology
- Merck
- Hangzhou Hs-biopharm
- Wuxibiologics
- Bioinnobio
- Thousand Oaks Biopharmaceuticals
- Cerbios-Pharma SA
- Eurogentec
- HJB
- Bibo Pharma
- MabPlex International
- Genscriptprobio
- Vetter
- Etinpro (Beijing) Co
- Boehringer Ingelheim BioXcellence
- Lonza
- 3SBio Inc
- Porton
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Antibody and Recombinant Protein CDMO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Antibody and Recombinant Protein CDMO, with revenue, gross margin and global market share of Antibody and Recombinant Protein CDMO from 2018 to 2023.
Chapter 3, the Antibody and Recombinant Protein CDMO competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Antibody and Recombinant Protein CDMO market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Antibody and Recombinant Protein CDMO.
Chapter 13, to describe Antibody and Recombinant Protein CDMO research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Antibody and Recombinant Protein CDMO
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Antibody and Recombinant Protein CDMO by Type
1.3.1 Overview: Global Antibody and Recombinant Protein CDMO Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Antibody and Recombinant Protein CDMO Consumption Value Market Share by Type in 2022
1.3.3 Antibody CDMO
1.3.4 Recombinant Protein CDMO
1.4 Global Antibody and Recombinant Protein CDMO Market by Application
1.4.1 Overview: Global Antibody and Recombinant Protein CDMO Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Pharmaceutical Company
1.4.3 Biotechnology Company
1.4.4 Generic Company
1.5 Global Antibody and Recombinant Protein CDMO Market Size & Forecast
1.6 Global Antibody and Recombinant Protein CDMO Market Size and Forecast by Region
1.6.1 Global Antibody and Recombinant Protein CDMO Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Antibody and Recombinant Protein CDMO Market Size by Region, (2018-2029)
1.6.3 North America Antibody and Recombinant Protein CDMO Market Size and Prospect (2018-2029)
1.6.4 Europe Antibody and Recombinant Protein CDMO Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Antibody and Recombinant Protein CDMO Market Size and Prospect (2018-2029)
1.6.6 South America Antibody and Recombinant Protein CDMO Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Antibody and Recombinant Protein CDMO Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Batavia Biosciences
2.1.1 Batavia Biosciences Details
2.1.2 Batavia Biosciences Major Business
2.1.3 Batavia Biosciences Antibody and Recombinant Protein CDMO Product and Solutions
2.1.4 Batavia Biosciences Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Batavia Biosciences Recent Developments and Future Plans
2.2 Grifols
2.2.1 Grifols Details
2.2.2 Grifols Major Business
2.2.3 Grifols Antibody and Recombinant Protein CDMO Product and Solutions
2.2.4 Grifols Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Grifols Recent Developments and Future Plans
2.3 Cerbios-Pharma SA
2.3.1 Cerbios-Pharma SA Details
2.3.2 Cerbios-Pharma SA Major Business
2.3.3 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Product and Solutions
2.3.4 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Cerbios-Pharma SA Recent Developments and Future Plans
2.4 HALIX
2.4.1 HALIX Details
2.4.2 HALIX Major Business
2.4.3 HALIX Antibody and Recombinant Protein CDMO Product and Solutions
2.4.4 HALIX Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 HALIX Recent Developments and Future Plans
2.5 Biovian Oy
2.5.1 Biovian Oy Details
2.5.2 Biovian Oy Major Business
2.5.3 Biovian Oy Antibody and Recombinant Protein CDMO Product and Solutions
2.5.4 Biovian Oy Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Biovian Oy Recent Developments and Future Plans
2.6 Catalent
2.6.1 Catalent Details
2.6.2 Catalent Major Business
2.6.3 Catalent Antibody and Recombinant Protein CDMO Product and Solutions
2.6.4 Catalent Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Catalent Recent Developments and Future Plans
2.7 Goodwin Biotechnology
2.7.1 Goodwin Biotechnology Details
2.7.2 Goodwin Biotechnology Major Business
2.7.3 Goodwin Biotechnology Antibody and Recombinant Protein CDMO Product and Solutions
2.7.4 Goodwin Biotechnology Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Goodwin Biotechnology Recent Developments and Future Plans
2.8 Merck
2.8.1 Merck Details
2.8.2 Merck Major Business
2.8.3 Merck Antibody and Recombinant Protein CDMO Product and Solutions
2.8.4 Merck Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Merck Recent Developments and Future Plans
2.9 Hangzhou Hs-biopharm
2.9.1 Hangzhou Hs-biopharm Details
2.9.2 Hangzhou Hs-biopharm Major Business
2.9.3 Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Product and Solutions
2.9.4 Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Hangzhou Hs-biopharm Recent Developments and Future Plans
2.10 Wuxibiologics
2.10.1 Wuxibiologics Details
2.10.2 Wuxibiologics Major Business
2.10.3 Wuxibiologics Antibody and Recombinant Protein CDMO Product and Solutions
2.10.4 Wuxibiologics Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Wuxibiologics Recent Developments and Future Plans
2.11 Bioinnobio
2.11.1 Bioinnobio Details
2.11.2 Bioinnobio Major Business
2.11.3 Bioinnobio Antibody and Recombinant Protein CDMO Product and Solutions
2.11.4 Bioinnobio Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Bioinnobio Recent Developments and Future Plans
2.12 Thousand Oaks Biopharmaceuticals
2.12.1 Thousand Oaks Biopharmaceuticals Details
2.12.2 Thousand Oaks Biopharmaceuticals Major Business
2.12.3 Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Product and Solutions
2.12.4 Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Thousand Oaks Biopharmaceuticals Recent Developments and Future Plans
2.13 Cerbios-Pharma SA
2.13.1 Cerbios-Pharma SA Details
2.13.2 Cerbios-Pharma SA Major Business
2.13.3 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Product and Solutions
2.13.4 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Cerbios-Pharma SA Recent Developments and Future Plans
2.14 Eurogentec
2.14.1 Eurogentec Details
2.14.2 Eurogentec Major Business
2.14.3 Eurogentec Antibody and Recombinant Protein CDMO Product and Solutions
2.14.4 Eurogentec Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Eurogentec Recent Developments and Future Plans
2.15 HJB
2.15.1 HJB Details
2.15.2 HJB Major Business
2.15.3 HJB Antibody and Recombinant Protein CDMO Product and Solutions
2.15.4 HJB Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 HJB Recent Developments and Future Plans
2.16 Bibo Pharma
2.16.1 Bibo Pharma Details
2.16.2 Bibo Pharma Major Business
2.16.3 Bibo Pharma Antibody and Recombinant Protein CDMO Product and Solutions
2.16.4 Bibo Pharma Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Bibo Pharma Recent Developments and Future Plans
2.17 MabPlex International
2.17.1 MabPlex International Details
2.17.2 MabPlex International Major Business
2.17.3 MabPlex International Antibody and Recombinant Protein CDMO Product and Solutions
2.17.4 MabPlex International Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 MabPlex International Recent Developments and Future Plans
2.18 Genscriptprobio
2.18.1 Genscriptprobio Details
2.18.2 Genscriptprobio Major Business
2.18.3 Genscriptprobio Antibody and Recombinant Protein CDMO Product and Solutions
2.18.4 Genscriptprobio Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Genscriptprobio Recent Developments and Future Plans
2.19 Vetter
2.19.1 Vetter Details
2.19.2 Vetter Major Business
2.19.3 Vetter Antibody and Recombinant Protein CDMO Product and Solutions
2.19.4 Vetter Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.19.5 Vetter Recent Developments and Future Plans
2.20 Etinpro (Beijing) Co
2.20.1 Etinpro (Beijing) Co Details
2.20.2 Etinpro (Beijing) Co Major Business
2.20.3 Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Product and Solutions
2.20.4 Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.20.5 Etinpro (Beijing) Co Recent Developments and Future Plans
2.21 Boehringer Ingelheim BioXcellence
2.21.1 Boehringer Ingelheim BioXcellence Details
2.21.2 Boehringer Ingelheim BioXcellence Major Business
2.21.3 Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Product and Solutions
2.21.4 Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.21.5 Boehringer Ingelheim BioXcellence Recent Developments and Future Plans
2.22 Lonza
2.22.1 Lonza Details
2.22.2 Lonza Major Business
2.22.3 Lonza Antibody and Recombinant Protein CDMO Product and Solutions
2.22.4 Lonza Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.22.5 Lonza Recent Developments and Future Plans
2.23 3SBio Inc
2.23.1 3SBio Inc Details
2.23.2 3SBio Inc Major Business
2.23.3 3SBio Inc Antibody and Recombinant Protein CDMO Product and Solutions
2.23.4 3SBio Inc Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.23.5 3SBio Inc Recent Developments and Future Plans
2.24 Porton
2.24.1 Porton Details
2.24.2 Porton Major Business
2.24.3 Porton Antibody and Recombinant Protein CDMO Product and Solutions
2.24.4 Porton Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.24.5 Porton Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Antibody and Recombinant Protein CDMO Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Antibody and Recombinant Protein CDMO by Company Revenue
3.2.2 Top 3 Antibody and Recombinant Protein CDMO Players Market Share in 2022
3.2.3 Top 6 Antibody and Recombinant Protein CDMO Players Market Share in 2022
3.3 Antibody and Recombinant Protein CDMO Market: Overall Company Footprint Analysis
3.3.1 Antibody and Recombinant Protein CDMO Market: Region Footprint
3.3.2 Antibody and Recombinant Protein CDMO Market: Company Product Type Footprint
3.3.3 Antibody and Recombinant Protein CDMO Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Antibody and Recombinant Protein CDMO Consumption Value and Market Share by Type (2018-2023)
4.2 Global Antibody and Recombinant Protein CDMO Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Antibody and Recombinant Protein CDMO Consumption Value Market Share by Application (2018-2023)
5.2 Global Antibody and Recombinant Protein CDMO Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Antibody and Recombinant Protein CDMO Consumption Value by Type (2018-2029)
6.2 North America Antibody and Recombinant Protein CDMO Consumption Value by Application (2018-2029)
6.3 North America Antibody and Recombinant Protein CDMO Market Size by Country
6.3.1 North America Antibody and Recombinant Protein CDMO Consumption Value by Country (2018-2029)
6.3.2 United States Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
6.3.3 Canada Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
6.3.4 Mexico Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Antibody and Recombinant Protein CDMO Consumption Value by Type (2018-2029)
7.2 Europe Antibody and Recombinant Protein CDMO Consumption Value by Application (2018-2029)
7.3 Europe Antibody and Recombinant Protein CDMO Market Size by Country
7.3.1 Europe Antibody and Recombinant Protein CDMO Consumption Value by Country (2018-2029)
7.3.2 Germany Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
7.3.3 France Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
7.3.5 Russia Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
7.3.6 Italy Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Antibody and Recombinant Protein CDMO Market Size by Region
8.3.1 Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value by Region (2018-2029)
8.3.2 China Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
8.3.3 Japan Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
8.3.4 South Korea Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
8.3.5 India Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
8.3.7 Australia Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Antibody and Recombinant Protein CDMO Consumption Value by Type (2018-2029)
9.2 South America Antibody and Recombinant Protein CDMO Consumption Value by Application (2018-2029)
9.3 South America Antibody and Recombinant Protein CDMO Market Size by Country
9.3.1 South America Antibody and Recombinant Protein CDMO Consumption Value by Country (2018-2029)
9.3.2 Brazil Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
9.3.3 Argentina Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Antibody and Recombinant Protein CDMO Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Antibody and Recombinant Protein CDMO Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Antibody and Recombinant Protein CDMO Market Size by Country
10.3.1 Middle East & Africa Antibody and Recombinant Protein CDMO Consumption Value by Country (2018-2029)
10.3.2 Turkey Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
10.3.4 UAE Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Antibody and Recombinant Protein CDMO Market Drivers
11.2 Antibody and Recombinant Protein CDMO Market Restraints
11.3 Antibody and Recombinant Protein CDMO Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Antibody and Recombinant Protein CDMO Industry Chain
12.2 Antibody and Recombinant Protein CDMO Upstream Analysis
12.3 Antibody and Recombinant Protein CDMO Midstream Analysis
12.4 Antibody and Recombinant Protein CDMO Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Antibody and Recombinant Protein CDMO
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Antibody and Recombinant Protein CDMO by Type
1.3.1 Overview: Global Antibody and Recombinant Protein CDMO Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Antibody and Recombinant Protein CDMO Consumption Value Market Share by Type in 2022
1.3.3 Antibody CDMO
1.3.4 Recombinant Protein CDMO
1.4 Global Antibody and Recombinant Protein CDMO Market by Application
1.4.1 Overview: Global Antibody and Recombinant Protein CDMO Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Pharmaceutical Company
1.4.3 Biotechnology Company
1.4.4 Generic Company
1.5 Global Antibody and Recombinant Protein CDMO Market Size & Forecast
1.6 Global Antibody and Recombinant Protein CDMO Market Size and Forecast by Region
1.6.1 Global Antibody and Recombinant Protein CDMO Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Antibody and Recombinant Protein CDMO Market Size by Region, (2018-2029)
1.6.3 North America Antibody and Recombinant Protein CDMO Market Size and Prospect (2018-2029)
1.6.4 Europe Antibody and Recombinant Protein CDMO Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Antibody and Recombinant Protein CDMO Market Size and Prospect (2018-2029)
1.6.6 South America Antibody and Recombinant Protein CDMO Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Antibody and Recombinant Protein CDMO Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Batavia Biosciences
2.1.1 Batavia Biosciences Details
2.1.2 Batavia Biosciences Major Business
2.1.3 Batavia Biosciences Antibody and Recombinant Protein CDMO Product and Solutions
2.1.4 Batavia Biosciences Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Batavia Biosciences Recent Developments and Future Plans
2.2 Grifols
2.2.1 Grifols Details
2.2.2 Grifols Major Business
2.2.3 Grifols Antibody and Recombinant Protein CDMO Product and Solutions
2.2.4 Grifols Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Grifols Recent Developments and Future Plans
2.3 Cerbios-Pharma SA
2.3.1 Cerbios-Pharma SA Details
2.3.2 Cerbios-Pharma SA Major Business
2.3.3 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Product and Solutions
2.3.4 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Cerbios-Pharma SA Recent Developments and Future Plans
2.4 HALIX
2.4.1 HALIX Details
2.4.2 HALIX Major Business
2.4.3 HALIX Antibody and Recombinant Protein CDMO Product and Solutions
2.4.4 HALIX Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 HALIX Recent Developments and Future Plans
2.5 Biovian Oy
2.5.1 Biovian Oy Details
2.5.2 Biovian Oy Major Business
2.5.3 Biovian Oy Antibody and Recombinant Protein CDMO Product and Solutions
2.5.4 Biovian Oy Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Biovian Oy Recent Developments and Future Plans
2.6 Catalent
2.6.1 Catalent Details
2.6.2 Catalent Major Business
2.6.3 Catalent Antibody and Recombinant Protein CDMO Product and Solutions
2.6.4 Catalent Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Catalent Recent Developments and Future Plans
2.7 Goodwin Biotechnology
2.7.1 Goodwin Biotechnology Details
2.7.2 Goodwin Biotechnology Major Business
2.7.3 Goodwin Biotechnology Antibody and Recombinant Protein CDMO Product and Solutions
2.7.4 Goodwin Biotechnology Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Goodwin Biotechnology Recent Developments and Future Plans
2.8 Merck
2.8.1 Merck Details
2.8.2 Merck Major Business
2.8.3 Merck Antibody and Recombinant Protein CDMO Product and Solutions
2.8.4 Merck Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Merck Recent Developments and Future Plans
2.9 Hangzhou Hs-biopharm
2.9.1 Hangzhou Hs-biopharm Details
2.9.2 Hangzhou Hs-biopharm Major Business
2.9.3 Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Product and Solutions
2.9.4 Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Hangzhou Hs-biopharm Recent Developments and Future Plans
2.10 Wuxibiologics
2.10.1 Wuxibiologics Details
2.10.2 Wuxibiologics Major Business
2.10.3 Wuxibiologics Antibody and Recombinant Protein CDMO Product and Solutions
2.10.4 Wuxibiologics Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Wuxibiologics Recent Developments and Future Plans
2.11 Bioinnobio
2.11.1 Bioinnobio Details
2.11.2 Bioinnobio Major Business
2.11.3 Bioinnobio Antibody and Recombinant Protein CDMO Product and Solutions
2.11.4 Bioinnobio Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Bioinnobio Recent Developments and Future Plans
2.12 Thousand Oaks Biopharmaceuticals
2.12.1 Thousand Oaks Biopharmaceuticals Details
2.12.2 Thousand Oaks Biopharmaceuticals Major Business
2.12.3 Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Product and Solutions
2.12.4 Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Thousand Oaks Biopharmaceuticals Recent Developments and Future Plans
2.13 Cerbios-Pharma SA
2.13.1 Cerbios-Pharma SA Details
2.13.2 Cerbios-Pharma SA Major Business
2.13.3 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Product and Solutions
2.13.4 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Cerbios-Pharma SA Recent Developments and Future Plans
2.14 Eurogentec
2.14.1 Eurogentec Details
2.14.2 Eurogentec Major Business
2.14.3 Eurogentec Antibody and Recombinant Protein CDMO Product and Solutions
2.14.4 Eurogentec Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Eurogentec Recent Developments and Future Plans
2.15 HJB
2.15.1 HJB Details
2.15.2 HJB Major Business
2.15.3 HJB Antibody and Recombinant Protein CDMO Product and Solutions
2.15.4 HJB Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 HJB Recent Developments and Future Plans
2.16 Bibo Pharma
2.16.1 Bibo Pharma Details
2.16.2 Bibo Pharma Major Business
2.16.3 Bibo Pharma Antibody and Recombinant Protein CDMO Product and Solutions
2.16.4 Bibo Pharma Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Bibo Pharma Recent Developments and Future Plans
2.17 MabPlex International
2.17.1 MabPlex International Details
2.17.2 MabPlex International Major Business
2.17.3 MabPlex International Antibody and Recombinant Protein CDMO Product and Solutions
2.17.4 MabPlex International Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 MabPlex International Recent Developments and Future Plans
2.18 Genscriptprobio
2.18.1 Genscriptprobio Details
2.18.2 Genscriptprobio Major Business
2.18.3 Genscriptprobio Antibody and Recombinant Protein CDMO Product and Solutions
2.18.4 Genscriptprobio Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Genscriptprobio Recent Developments and Future Plans
2.19 Vetter
2.19.1 Vetter Details
2.19.2 Vetter Major Business
2.19.3 Vetter Antibody and Recombinant Protein CDMO Product and Solutions
2.19.4 Vetter Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.19.5 Vetter Recent Developments and Future Plans
2.20 Etinpro (Beijing) Co
2.20.1 Etinpro (Beijing) Co Details
2.20.2 Etinpro (Beijing) Co Major Business
2.20.3 Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Product and Solutions
2.20.4 Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.20.5 Etinpro (Beijing) Co Recent Developments and Future Plans
2.21 Boehringer Ingelheim BioXcellence
2.21.1 Boehringer Ingelheim BioXcellence Details
2.21.2 Boehringer Ingelheim BioXcellence Major Business
2.21.3 Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Product and Solutions
2.21.4 Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.21.5 Boehringer Ingelheim BioXcellence Recent Developments and Future Plans
2.22 Lonza
2.22.1 Lonza Details
2.22.2 Lonza Major Business
2.22.3 Lonza Antibody and Recombinant Protein CDMO Product and Solutions
2.22.4 Lonza Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.22.5 Lonza Recent Developments and Future Plans
2.23 3SBio Inc
2.23.1 3SBio Inc Details
2.23.2 3SBio Inc Major Business
2.23.3 3SBio Inc Antibody and Recombinant Protein CDMO Product and Solutions
2.23.4 3SBio Inc Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.23.5 3SBio Inc Recent Developments and Future Plans
2.24 Porton
2.24.1 Porton Details
2.24.2 Porton Major Business
2.24.3 Porton Antibody and Recombinant Protein CDMO Product and Solutions
2.24.4 Porton Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.24.5 Porton Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Antibody and Recombinant Protein CDMO Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Antibody and Recombinant Protein CDMO by Company Revenue
3.2.2 Top 3 Antibody and Recombinant Protein CDMO Players Market Share in 2022
3.2.3 Top 6 Antibody and Recombinant Protein CDMO Players Market Share in 2022
3.3 Antibody and Recombinant Protein CDMO Market: Overall Company Footprint Analysis
3.3.1 Antibody and Recombinant Protein CDMO Market: Region Footprint
3.3.2 Antibody and Recombinant Protein CDMO Market: Company Product Type Footprint
3.3.3 Antibody and Recombinant Protein CDMO Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Antibody and Recombinant Protein CDMO Consumption Value and Market Share by Type (2018-2023)
4.2 Global Antibody and Recombinant Protein CDMO Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Antibody and Recombinant Protein CDMO Consumption Value Market Share by Application (2018-2023)
5.2 Global Antibody and Recombinant Protein CDMO Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Antibody and Recombinant Protein CDMO Consumption Value by Type (2018-2029)
6.2 North America Antibody and Recombinant Protein CDMO Consumption Value by Application (2018-2029)
6.3 North America Antibody and Recombinant Protein CDMO Market Size by Country
6.3.1 North America Antibody and Recombinant Protein CDMO Consumption Value by Country (2018-2029)
6.3.2 United States Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
6.3.3 Canada Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
6.3.4 Mexico Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Antibody and Recombinant Protein CDMO Consumption Value by Type (2018-2029)
7.2 Europe Antibody and Recombinant Protein CDMO Consumption Value by Application (2018-2029)
7.3 Europe Antibody and Recombinant Protein CDMO Market Size by Country
7.3.1 Europe Antibody and Recombinant Protein CDMO Consumption Value by Country (2018-2029)
7.3.2 Germany Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
7.3.3 France Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
7.3.5 Russia Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
7.3.6 Italy Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Antibody and Recombinant Protein CDMO Market Size by Region
8.3.1 Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value by Region (2018-2029)
8.3.2 China Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
8.3.3 Japan Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
8.3.4 South Korea Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
8.3.5 India Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
8.3.7 Australia Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Antibody and Recombinant Protein CDMO Consumption Value by Type (2018-2029)
9.2 South America Antibody and Recombinant Protein CDMO Consumption Value by Application (2018-2029)
9.3 South America Antibody and Recombinant Protein CDMO Market Size by Country
9.3.1 South America Antibody and Recombinant Protein CDMO Consumption Value by Country (2018-2029)
9.3.2 Brazil Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
9.3.3 Argentina Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Antibody and Recombinant Protein CDMO Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Antibody and Recombinant Protein CDMO Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Antibody and Recombinant Protein CDMO Market Size by Country
10.3.1 Middle East & Africa Antibody and Recombinant Protein CDMO Consumption Value by Country (2018-2029)
10.3.2 Turkey Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
10.3.4 UAE Antibody and Recombinant Protein CDMO Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Antibody and Recombinant Protein CDMO Market Drivers
11.2 Antibody and Recombinant Protein CDMO Market Restraints
11.3 Antibody and Recombinant Protein CDMO Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Antibody and Recombinant Protein CDMO Industry Chain
12.2 Antibody and Recombinant Protein CDMO Upstream Analysis
12.3 Antibody and Recombinant Protein CDMO Midstream Analysis
12.4 Antibody and Recombinant Protein CDMO Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Antibody and Recombinant Protein CDMO Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Antibody and Recombinant Protein CDMO Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Antibody and Recombinant Protein CDMO Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Antibody and Recombinant Protein CDMO Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Batavia Biosciences Company Information, Head Office, and Major Competitors
Table 6. Batavia Biosciences Major Business
Table 7. Batavia Biosciences Antibody and Recombinant Protein CDMO Product and Solutions
Table 8. Batavia Biosciences Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Batavia Biosciences Recent Developments and Future Plans
Table 10. Grifols Company Information, Head Office, and Major Competitors
Table 11. Grifols Major Business
Table 12. Grifols Antibody and Recombinant Protein CDMO Product and Solutions
Table 13. Grifols Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Grifols Recent Developments and Future Plans
Table 15. Cerbios-Pharma SA Company Information, Head Office, and Major Competitors
Table 16. Cerbios-Pharma SA Major Business
Table 17. Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Product and Solutions
Table 18. Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Cerbios-Pharma SA Recent Developments and Future Plans
Table 20. HALIX Company Information, Head Office, and Major Competitors
Table 21. HALIX Major Business
Table 22. HALIX Antibody and Recombinant Protein CDMO Product and Solutions
Table 23. HALIX Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. HALIX Recent Developments and Future Plans
Table 25. Biovian Oy Company Information, Head Office, and Major Competitors
Table 26. Biovian Oy Major Business
Table 27. Biovian Oy Antibody and Recombinant Protein CDMO Product and Solutions
Table 28. Biovian Oy Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Biovian Oy Recent Developments and Future Plans
Table 30. Catalent Company Information, Head Office, and Major Competitors
Table 31. Catalent Major Business
Table 32. Catalent Antibody and Recombinant Protein CDMO Product and Solutions
Table 33. Catalent Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Catalent Recent Developments and Future Plans
Table 35. Goodwin Biotechnology Company Information, Head Office, and Major Competitors
Table 36. Goodwin Biotechnology Major Business
Table 37. Goodwin Biotechnology Antibody and Recombinant Protein CDMO Product and Solutions
Table 38. Goodwin Biotechnology Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Goodwin Biotechnology Recent Developments and Future Plans
Table 40. Merck Company Information, Head Office, and Major Competitors
Table 41. Merck Major Business
Table 42. Merck Antibody and Recombinant Protein CDMO Product and Solutions
Table 43. Merck Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Merck Recent Developments and Future Plans
Table 45. Hangzhou Hs-biopharm Company Information, Head Office, and Major Competitors
Table 46. Hangzhou Hs-biopharm Major Business
Table 47. Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Product and Solutions
Table 48. Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Hangzhou Hs-biopharm Recent Developments and Future Plans
Table 50. Wuxibiologics Company Information, Head Office, and Major Competitors
Table 51. Wuxibiologics Major Business
Table 52. Wuxibiologics Antibody and Recombinant Protein CDMO Product and Solutions
Table 53. Wuxibiologics Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Wuxibiologics Recent Developments and Future Plans
Table 55. Bioinnobio Company Information, Head Office, and Major Competitors
Table 56. Bioinnobio Major Business
Table 57. Bioinnobio Antibody and Recombinant Protein CDMO Product and Solutions
Table 58. Bioinnobio Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Bioinnobio Recent Developments and Future Plans
Table 60. Thousand Oaks Biopharmaceuticals Company Information, Head Office, and Major Competitors
Table 61. Thousand Oaks Biopharmaceuticals Major Business
Table 62. Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Product and Solutions
Table 63. Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Thousand Oaks Biopharmaceuticals Recent Developments and Future Plans
Table 65. Cerbios-Pharma SA Company Information, Head Office, and Major Competitors
Table 66. Cerbios-Pharma SA Major Business
Table 67. Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Product and Solutions
Table 68. Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Cerbios-Pharma SA Recent Developments and Future Plans
Table 70. Eurogentec Company Information, Head Office, and Major Competitors
Table 71. Eurogentec Major Business
Table 72. Eurogentec Antibody and Recombinant Protein CDMO Product and Solutions
Table 73. Eurogentec Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Eurogentec Recent Developments and Future Plans
Table 75. HJB Company Information, Head Office, and Major Competitors
Table 76. HJB Major Business
Table 77. HJB Antibody and Recombinant Protein CDMO Product and Solutions
Table 78. HJB Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. HJB Recent Developments and Future Plans
Table 80. Bibo Pharma Company Information, Head Office, and Major Competitors
Table 81. Bibo Pharma Major Business
Table 82. Bibo Pharma Antibody and Recombinant Protein CDMO Product and Solutions
Table 83. Bibo Pharma Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 84. Bibo Pharma Recent Developments and Future Plans
Table 85. MabPlex International Company Information, Head Office, and Major Competitors
Table 86. MabPlex International Major Business
Table 87. MabPlex International Antibody and Recombinant Protein CDMO Product and Solutions
Table 88. MabPlex International Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. MabPlex International Recent Developments and Future Plans
Table 90. Genscriptprobio Company Information, Head Office, and Major Competitors
Table 91. Genscriptprobio Major Business
Table 92. Genscriptprobio Antibody and Recombinant Protein CDMO Product and Solutions
Table 93. Genscriptprobio Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 94. Genscriptprobio Recent Developments and Future Plans
Table 95. Vetter Company Information, Head Office, and Major Competitors
Table 96. Vetter Major Business
Table 97. Vetter Antibody and Recombinant Protein CDMO Product and Solutions
Table 98. Vetter Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 99. Vetter Recent Developments and Future Plans
Table 100. Etinpro (Beijing) Co Company Information, Head Office, and Major Competitors
Table 101. Etinpro (Beijing) Co Major Business
Table 102. Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Product and Solutions
Table 103. Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 104. Etinpro (Beijing) Co Recent Developments and Future Plans
Table 105. Boehringer Ingelheim BioXcellence Company Information, Head Office, and Major Competitors
Table 106. Boehringer Ingelheim BioXcellence Major Business
Table 107. Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Product and Solutions
Table 108. Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 109. Boehringer Ingelheim BioXcellence Recent Developments and Future Plans
Table 110. Lonza Company Information, Head Office, and Major Competitors
Table 111. Lonza Major Business
Table 112. Lonza Antibody and Recombinant Protein CDMO Product and Solutions
Table 113. Lonza Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 114. Lonza Recent Developments and Future Plans
Table 115. 3SBio Inc Company Information, Head Office, and Major Competitors
Table 116. 3SBio Inc Major Business
Table 117. 3SBio Inc Antibody and Recombinant Protein CDMO Product and Solutions
Table 118. 3SBio Inc Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 119. 3SBio Inc Recent Developments and Future Plans
Table 120. Porton Company Information, Head Office, and Major Competitors
Table 121. Porton Major Business
Table 122. Porton Antibody and Recombinant Protein CDMO Product and Solutions
Table 123. Porton Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 124. Porton Recent Developments and Future Plans
Table 125. Global Antibody and Recombinant Protein CDMO Revenue (USD Million) by Players (2018-2023)
Table 126. Global Antibody and Recombinant Protein CDMO Revenue Share by Players (2018-2023)
Table 127. Breakdown of Antibody and Recombinant Protein CDMO by Company Type (Tier 1, Tier 2, and Tier 3)
Table 128. Market Position of Players in Antibody and Recombinant Protein CDMO, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 129. Head Office of Key Antibody and Recombinant Protein CDMO Players
Table 130. Antibody and Recombinant Protein CDMO Market: Company Product Type Footprint
Table 131. Antibody and Recombinant Protein CDMO Market: Company Product Application Footprint
Table 132. Antibody and Recombinant Protein CDMO New Market Entrants and Barriers to Market Entry
Table 133. Antibody and Recombinant Protein CDMO Mergers, Acquisition, Agreements, and Collaborations
Table 134. Global Antibody and Recombinant Protein CDMO Consumption Value (USD Million) by Type (2018-2023)
Table 135. Global Antibody and Recombinant Protein CDMO Consumption Value Share by Type (2018-2023)
Table 136. Global Antibody and Recombinant Protein CDMO Consumption Value Forecast by Type (2024-2029)
Table 137. Global Antibody and Recombinant Protein CDMO Consumption Value by Application (2018-2023)
Table 138. Global Antibody and Recombinant Protein CDMO Consumption Value Forecast by Application (2024-2029)
Table 139. North America Antibody and Recombinant Protein CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 140. North America Antibody and Recombinant Protein CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 141. North America Antibody and Recombinant Protein CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 142. North America Antibody and Recombinant Protein CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 143. North America Antibody and Recombinant Protein CDMO Consumption Value by Country (2018-2023) & (USD Million)
Table 144. North America Antibody and Recombinant Protein CDMO Consumption Value by Country (2024-2029) & (USD Million)
Table 145. Europe Antibody and Recombinant Protein CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 146. Europe Antibody and Recombinant Protein CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 147. Europe Antibody and Recombinant Protein CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 148. Europe Antibody and Recombinant Protein CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 149. Europe Antibody and Recombinant Protein CDMO Consumption Value by Country (2018-2023) & (USD Million)
Table 150. Europe Antibody and Recombinant Protein CDMO Consumption Value by Country (2024-2029) & (USD Million)
Table 151. Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 152. Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 153. Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 154. Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 155. Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value by Region (2018-2023) & (USD Million)
Table 156. Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value by Region (2024-2029) & (USD Million)
Table 157. South America Antibody and Recombinant Protein CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 158. South America Antibody and Recombinant Protein CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 159. South America Antibody and Recombinant Protein CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 160. South America Antibody and Recombinant Protein CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 161. South America Antibody and Recombinant Protein CDMO Consumption Value by Country (2018-2023) & (USD Million)
Table 162. South America Antibody and Recombinant Protein CDMO Consumption Value by Country (2024-2029) & (USD Million)
Table 163. Middle East & Africa Antibody and Recombinant Protein CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 164. Middle East & Africa Antibody and Recombinant Protein CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 165. Middle East & Africa Antibody and Recombinant Protein CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 166. Middle East & Africa Antibody and Recombinant Protein CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 167. Middle East & Africa Antibody and Recombinant Protein CDMO Consumption Value by Country (2018-2023) & (USD Million)
Table 168. Middle East & Africa Antibody and Recombinant Protein CDMO Consumption Value by Country (2024-2029) & (USD Million)
Table 169. Antibody and Recombinant Protein CDMO Raw Material
Table 170. Key Suppliers of Antibody and Recombinant Protein CDMO Raw Materials
Table 1. Global Antibody and Recombinant Protein CDMO Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Antibody and Recombinant Protein CDMO Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Antibody and Recombinant Protein CDMO Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Antibody and Recombinant Protein CDMO Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Batavia Biosciences Company Information, Head Office, and Major Competitors
Table 6. Batavia Biosciences Major Business
Table 7. Batavia Biosciences Antibody and Recombinant Protein CDMO Product and Solutions
Table 8. Batavia Biosciences Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Batavia Biosciences Recent Developments and Future Plans
Table 10. Grifols Company Information, Head Office, and Major Competitors
Table 11. Grifols Major Business
Table 12. Grifols Antibody and Recombinant Protein CDMO Product and Solutions
Table 13. Grifols Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Grifols Recent Developments and Future Plans
Table 15. Cerbios-Pharma SA Company Information, Head Office, and Major Competitors
Table 16. Cerbios-Pharma SA Major Business
Table 17. Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Product and Solutions
Table 18. Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Cerbios-Pharma SA Recent Developments and Future Plans
Table 20. HALIX Company Information, Head Office, and Major Competitors
Table 21. HALIX Major Business
Table 22. HALIX Antibody and Recombinant Protein CDMO Product and Solutions
Table 23. HALIX Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. HALIX Recent Developments and Future Plans
Table 25. Biovian Oy Company Information, Head Office, and Major Competitors
Table 26. Biovian Oy Major Business
Table 27. Biovian Oy Antibody and Recombinant Protein CDMO Product and Solutions
Table 28. Biovian Oy Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Biovian Oy Recent Developments and Future Plans
Table 30. Catalent Company Information, Head Office, and Major Competitors
Table 31. Catalent Major Business
Table 32. Catalent Antibody and Recombinant Protein CDMO Product and Solutions
Table 33. Catalent Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Catalent Recent Developments and Future Plans
Table 35. Goodwin Biotechnology Company Information, Head Office, and Major Competitors
Table 36. Goodwin Biotechnology Major Business
Table 37. Goodwin Biotechnology Antibody and Recombinant Protein CDMO Product and Solutions
Table 38. Goodwin Biotechnology Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Goodwin Biotechnology Recent Developments and Future Plans
Table 40. Merck Company Information, Head Office, and Major Competitors
Table 41. Merck Major Business
Table 42. Merck Antibody and Recombinant Protein CDMO Product and Solutions
Table 43. Merck Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Merck Recent Developments and Future Plans
Table 45. Hangzhou Hs-biopharm Company Information, Head Office, and Major Competitors
Table 46. Hangzhou Hs-biopharm Major Business
Table 47. Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Product and Solutions
Table 48. Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Hangzhou Hs-biopharm Recent Developments and Future Plans
Table 50. Wuxibiologics Company Information, Head Office, and Major Competitors
Table 51. Wuxibiologics Major Business
Table 52. Wuxibiologics Antibody and Recombinant Protein CDMO Product and Solutions
Table 53. Wuxibiologics Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Wuxibiologics Recent Developments and Future Plans
Table 55. Bioinnobio Company Information, Head Office, and Major Competitors
Table 56. Bioinnobio Major Business
Table 57. Bioinnobio Antibody and Recombinant Protein CDMO Product and Solutions
Table 58. Bioinnobio Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Bioinnobio Recent Developments and Future Plans
Table 60. Thousand Oaks Biopharmaceuticals Company Information, Head Office, and Major Competitors
Table 61. Thousand Oaks Biopharmaceuticals Major Business
Table 62. Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Product and Solutions
Table 63. Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Thousand Oaks Biopharmaceuticals Recent Developments and Future Plans
Table 65. Cerbios-Pharma SA Company Information, Head Office, and Major Competitors
Table 66. Cerbios-Pharma SA Major Business
Table 67. Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Product and Solutions
Table 68. Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Cerbios-Pharma SA Recent Developments and Future Plans
Table 70. Eurogentec Company Information, Head Office, and Major Competitors
Table 71. Eurogentec Major Business
Table 72. Eurogentec Antibody and Recombinant Protein CDMO Product and Solutions
Table 73. Eurogentec Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Eurogentec Recent Developments and Future Plans
Table 75. HJB Company Information, Head Office, and Major Competitors
Table 76. HJB Major Business
Table 77. HJB Antibody and Recombinant Protein CDMO Product and Solutions
Table 78. HJB Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. HJB Recent Developments and Future Plans
Table 80. Bibo Pharma Company Information, Head Office, and Major Competitors
Table 81. Bibo Pharma Major Business
Table 82. Bibo Pharma Antibody and Recombinant Protein CDMO Product and Solutions
Table 83. Bibo Pharma Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 84. Bibo Pharma Recent Developments and Future Plans
Table 85. MabPlex International Company Information, Head Office, and Major Competitors
Table 86. MabPlex International Major Business
Table 87. MabPlex International Antibody and Recombinant Protein CDMO Product and Solutions
Table 88. MabPlex International Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. MabPlex International Recent Developments and Future Plans
Table 90. Genscriptprobio Company Information, Head Office, and Major Competitors
Table 91. Genscriptprobio Major Business
Table 92. Genscriptprobio Antibody and Recombinant Protein CDMO Product and Solutions
Table 93. Genscriptprobio Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 94. Genscriptprobio Recent Developments and Future Plans
Table 95. Vetter Company Information, Head Office, and Major Competitors
Table 96. Vetter Major Business
Table 97. Vetter Antibody and Recombinant Protein CDMO Product and Solutions
Table 98. Vetter Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 99. Vetter Recent Developments and Future Plans
Table 100. Etinpro (Beijing) Co Company Information, Head Office, and Major Competitors
Table 101. Etinpro (Beijing) Co Major Business
Table 102. Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Product and Solutions
Table 103. Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 104. Etinpro (Beijing) Co Recent Developments and Future Plans
Table 105. Boehringer Ingelheim BioXcellence Company Information, Head Office, and Major Competitors
Table 106. Boehringer Ingelheim BioXcellence Major Business
Table 107. Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Product and Solutions
Table 108. Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 109. Boehringer Ingelheim BioXcellence Recent Developments and Future Plans
Table 110. Lonza Company Information, Head Office, and Major Competitors
Table 111. Lonza Major Business
Table 112. Lonza Antibody and Recombinant Protein CDMO Product and Solutions
Table 113. Lonza Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 114. Lonza Recent Developments and Future Plans
Table 115. 3SBio Inc Company Information, Head Office, and Major Competitors
Table 116. 3SBio Inc Major Business
Table 117. 3SBio Inc Antibody and Recombinant Protein CDMO Product and Solutions
Table 118. 3SBio Inc Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 119. 3SBio Inc Recent Developments and Future Plans
Table 120. Porton Company Information, Head Office, and Major Competitors
Table 121. Porton Major Business
Table 122. Porton Antibody and Recombinant Protein CDMO Product and Solutions
Table 123. Porton Antibody and Recombinant Protein CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 124. Porton Recent Developments and Future Plans
Table 125. Global Antibody and Recombinant Protein CDMO Revenue (USD Million) by Players (2018-2023)
Table 126. Global Antibody and Recombinant Protein CDMO Revenue Share by Players (2018-2023)
Table 127. Breakdown of Antibody and Recombinant Protein CDMO by Company Type (Tier 1, Tier 2, and Tier 3)
Table 128. Market Position of Players in Antibody and Recombinant Protein CDMO, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 129. Head Office of Key Antibody and Recombinant Protein CDMO Players
Table 130. Antibody and Recombinant Protein CDMO Market: Company Product Type Footprint
Table 131. Antibody and Recombinant Protein CDMO Market: Company Product Application Footprint
Table 132. Antibody and Recombinant Protein CDMO New Market Entrants and Barriers to Market Entry
Table 133. Antibody and Recombinant Protein CDMO Mergers, Acquisition, Agreements, and Collaborations
Table 134. Global Antibody and Recombinant Protein CDMO Consumption Value (USD Million) by Type (2018-2023)
Table 135. Global Antibody and Recombinant Protein CDMO Consumption Value Share by Type (2018-2023)
Table 136. Global Antibody and Recombinant Protein CDMO Consumption Value Forecast by Type (2024-2029)
Table 137. Global Antibody and Recombinant Protein CDMO Consumption Value by Application (2018-2023)
Table 138. Global Antibody and Recombinant Protein CDMO Consumption Value Forecast by Application (2024-2029)
Table 139. North America Antibody and Recombinant Protein CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 140. North America Antibody and Recombinant Protein CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 141. North America Antibody and Recombinant Protein CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 142. North America Antibody and Recombinant Protein CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 143. North America Antibody and Recombinant Protein CDMO Consumption Value by Country (2018-2023) & (USD Million)
Table 144. North America Antibody and Recombinant Protein CDMO Consumption Value by Country (2024-2029) & (USD Million)
Table 145. Europe Antibody and Recombinant Protein CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 146. Europe Antibody and Recombinant Protein CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 147. Europe Antibody and Recombinant Protein CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 148. Europe Antibody and Recombinant Protein CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 149. Europe Antibody and Recombinant Protein CDMO Consumption Value by Country (2018-2023) & (USD Million)
Table 150. Europe Antibody and Recombinant Protein CDMO Consumption Value by Country (2024-2029) & (USD Million)
Table 151. Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 152. Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 153. Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 154. Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 155. Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value by Region (2018-2023) & (USD Million)
Table 156. Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value by Region (2024-2029) & (USD Million)
Table 157. South America Antibody and Recombinant Protein CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 158. South America Antibody and Recombinant Protein CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 159. South America Antibody and Recombinant Protein CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 160. South America Antibody and Recombinant Protein CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 161. South America Antibody and Recombinant Protein CDMO Consumption Value by Country (2018-2023) & (USD Million)
Table 162. South America Antibody and Recombinant Protein CDMO Consumption Value by Country (2024-2029) & (USD Million)
Table 163. Middle East & Africa Antibody and Recombinant Protein CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 164. Middle East & Africa Antibody and Recombinant Protein CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 165. Middle East & Africa Antibody and Recombinant Protein CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 166. Middle East & Africa Antibody and Recombinant Protein CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 167. Middle East & Africa Antibody and Recombinant Protein CDMO Consumption Value by Country (2018-2023) & (USD Million)
Table 168. Middle East & Africa Antibody and Recombinant Protein CDMO Consumption Value by Country (2024-2029) & (USD Million)
Table 169. Antibody and Recombinant Protein CDMO Raw Material
Table 170. Key Suppliers of Antibody and Recombinant Protein CDMO Raw Materials
LIST OF FIGURES
Figure 1. Antibody and Recombinant Protein CDMO Picture
Figure 2. Global Antibody and Recombinant Protein CDMO Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Antibody and Recombinant Protein CDMO Consumption Value Market Share by Type in 2022
Figure 4. Antibody CDMO
Figure 5. Recombinant Protein CDMO
Figure 6. Global Antibody and Recombinant Protein CDMO Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Antibody and Recombinant Protein CDMO Consumption Value Market Share by Application in 2022
Figure 8. Pharmaceutical Company Picture
Figure 9. Biotechnology Company Picture
Figure 10. Generic Company Picture
Figure 11. Global Antibody and Recombinant Protein CDMO Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global Antibody and Recombinant Protein CDMO Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global Market Antibody and Recombinant Protein CDMO Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 14. Global Antibody and Recombinant Protein CDMO Consumption Value Market Share by Region (2018-2029)
Figure 15. Global Antibody and Recombinant Protein CDMO Consumption Value Market Share by Region in 2022
Figure 16. North America Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 17. Europe Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 18. Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 19. South America Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 20. Middle East and Africa Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 21. Global Antibody and Recombinant Protein CDMO Revenue Share by Players in 2022
Figure 22. Antibody and Recombinant Protein CDMO Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 23. Global Top 3 Players Antibody and Recombinant Protein CDMO Market Share in 2022
Figure 24. Global Top 6 Players Antibody and Recombinant Protein CDMO Market Share in 2022
Figure 25. Global Antibody and Recombinant Protein CDMO Consumption Value Share by Type (2018-2023)
Figure 26. Global Antibody and Recombinant Protein CDMO Market Share Forecast by Type (2024-2029)
Figure 27. Global Antibody and Recombinant Protein CDMO Consumption Value Share by Application (2018-2023)
Figure 28. Global Antibody and Recombinant Protein CDMO Market Share Forecast by Application (2024-2029)
Figure 29. North America Antibody and Recombinant Protein CDMO Consumption Value Market Share by Type (2018-2029)
Figure 30. North America Antibody and Recombinant Protein CDMO Consumption Value Market Share by Application (2018-2029)
Figure 31. North America Antibody and Recombinant Protein CDMO Consumption Value Market Share by Country (2018-2029)
Figure 32. United States Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 33. Canada Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 34. Mexico Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 35. Europe Antibody and Recombinant Protein CDMO Consumption Value Market Share by Type (2018-2029)
Figure 36. Europe Antibody and Recombinant Protein CDMO Consumption Value Market Share by Application (2018-2029)
Figure 37. Europe Antibody and Recombinant Protein CDMO Consumption Value Market Share by Country (2018-2029)
Figure 38. Germany Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 39. France Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 40. United Kingdom Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 41. Russia Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 42. Italy Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 43. Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value Market Share by Type (2018-2029)
Figure 44. Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value Market Share by Application (2018-2029)
Figure 45. Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value Market Share by Region (2018-2029)
Figure 46. China Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 47. Japan Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 48. South Korea Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 49. India Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 50. Southeast Asia Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 51. Australia Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 52. South America Antibody and Recombinant Protein CDMO Consumption Value Market Share by Type (2018-2029)
Figure 53. South America Antibody and Recombinant Protein CDMO Consumption Value Market Share by Application (2018-2029)
Figure 54. South America Antibody and Recombinant Protein CDMO Consumption Value Market Share by Country (2018-2029)
Figure 55. Brazil Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 56. Argentina Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 57. Middle East and Africa Antibody and Recombinant Protein CDMO Consumption Value Market Share by Type (2018-2029)
Figure 58. Middle East and Africa Antibody and Recombinant Protein CDMO Consumption Value Market Share by Application (2018-2029)
Figure 59. Middle East and Africa Antibody and Recombinant Protein CDMO Consumption Value Market Share by Country (2018-2029)
Figure 60. Turkey Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 61. Saudi Arabia Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 62. UAE Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 63. Antibody and Recombinant Protein CDMO Market Drivers
Figure 64. Antibody and Recombinant Protein CDMO Market Restraints
Figure 65. Antibody and Recombinant Protein CDMO Market Trends
Figure 66. Porters Five Forces Analysis
Figure 67. Manufacturing Cost Structure Analysis of Antibody and Recombinant Protein CDMO in 2022
Figure 68. Manufacturing Process Analysis of Antibody and Recombinant Protein CDMO
Figure 69. Antibody and Recombinant Protein CDMO Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source
Figure 1. Antibody and Recombinant Protein CDMO Picture
Figure 2. Global Antibody and Recombinant Protein CDMO Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Antibody and Recombinant Protein CDMO Consumption Value Market Share by Type in 2022
Figure 4. Antibody CDMO
Figure 5. Recombinant Protein CDMO
Figure 6. Global Antibody and Recombinant Protein CDMO Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Antibody and Recombinant Protein CDMO Consumption Value Market Share by Application in 2022
Figure 8. Pharmaceutical Company Picture
Figure 9. Biotechnology Company Picture
Figure 10. Generic Company Picture
Figure 11. Global Antibody and Recombinant Protein CDMO Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global Antibody and Recombinant Protein CDMO Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global Market Antibody and Recombinant Protein CDMO Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 14. Global Antibody and Recombinant Protein CDMO Consumption Value Market Share by Region (2018-2029)
Figure 15. Global Antibody and Recombinant Protein CDMO Consumption Value Market Share by Region in 2022
Figure 16. North America Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 17. Europe Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 18. Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 19. South America Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 20. Middle East and Africa Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 21. Global Antibody and Recombinant Protein CDMO Revenue Share by Players in 2022
Figure 22. Antibody and Recombinant Protein CDMO Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 23. Global Top 3 Players Antibody and Recombinant Protein CDMO Market Share in 2022
Figure 24. Global Top 6 Players Antibody and Recombinant Protein CDMO Market Share in 2022
Figure 25. Global Antibody and Recombinant Protein CDMO Consumption Value Share by Type (2018-2023)
Figure 26. Global Antibody and Recombinant Protein CDMO Market Share Forecast by Type (2024-2029)
Figure 27. Global Antibody and Recombinant Protein CDMO Consumption Value Share by Application (2018-2023)
Figure 28. Global Antibody and Recombinant Protein CDMO Market Share Forecast by Application (2024-2029)
Figure 29. North America Antibody and Recombinant Protein CDMO Consumption Value Market Share by Type (2018-2029)
Figure 30. North America Antibody and Recombinant Protein CDMO Consumption Value Market Share by Application (2018-2029)
Figure 31. North America Antibody and Recombinant Protein CDMO Consumption Value Market Share by Country (2018-2029)
Figure 32. United States Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 33. Canada Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 34. Mexico Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 35. Europe Antibody and Recombinant Protein CDMO Consumption Value Market Share by Type (2018-2029)
Figure 36. Europe Antibody and Recombinant Protein CDMO Consumption Value Market Share by Application (2018-2029)
Figure 37. Europe Antibody and Recombinant Protein CDMO Consumption Value Market Share by Country (2018-2029)
Figure 38. Germany Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 39. France Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 40. United Kingdom Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 41. Russia Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 42. Italy Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 43. Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value Market Share by Type (2018-2029)
Figure 44. Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value Market Share by Application (2018-2029)
Figure 45. Asia-Pacific Antibody and Recombinant Protein CDMO Consumption Value Market Share by Region (2018-2029)
Figure 46. China Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 47. Japan Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 48. South Korea Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 49. India Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 50. Southeast Asia Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 51. Australia Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 52. South America Antibody and Recombinant Protein CDMO Consumption Value Market Share by Type (2018-2029)
Figure 53. South America Antibody and Recombinant Protein CDMO Consumption Value Market Share by Application (2018-2029)
Figure 54. South America Antibody and Recombinant Protein CDMO Consumption Value Market Share by Country (2018-2029)
Figure 55. Brazil Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 56. Argentina Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 57. Middle East and Africa Antibody and Recombinant Protein CDMO Consumption Value Market Share by Type (2018-2029)
Figure 58. Middle East and Africa Antibody and Recombinant Protein CDMO Consumption Value Market Share by Application (2018-2029)
Figure 59. Middle East and Africa Antibody and Recombinant Protein CDMO Consumption Value Market Share by Country (2018-2029)
Figure 60. Turkey Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 61. Saudi Arabia Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 62. UAE Antibody and Recombinant Protein CDMO Consumption Value (2018-2029) & (USD Million)
Figure 63. Antibody and Recombinant Protein CDMO Market Drivers
Figure 64. Antibody and Recombinant Protein CDMO Market Restraints
Figure 65. Antibody and Recombinant Protein CDMO Market Trends
Figure 66. Porters Five Forces Analysis
Figure 67. Manufacturing Cost Structure Analysis of Antibody and Recombinant Protein CDMO in 2022
Figure 68. Manufacturing Process Analysis of Antibody and Recombinant Protein CDMO
Figure 69. Antibody and Recombinant Protein CDMO Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source
